AdaptHealth Corp. 8-K Summary
Business Context and Reporting Period
AdaptHealth Corp. (AHCO), a Delaware corporation and emerging growth company, filed this Current Report on Form 8-K on July 29, 2020. The filing details significant capital structure changes, including the completion of a senior notes offering and the entry into a new credit agreement to refinance existing debt.
Key Financial Metrics and Capital Structure
- Senior Notes Offering: Completed an offering of $350 million aggregate principal amount of 6.125% Senior Notes due 2028.
- Notes Maturity: August 1, 2028.
- Notes Interest: Payable semi-annually on February 1 and August 1, commencing February 1, 2021.
- New Credit Agreement:
- Revolving Credit Facility: $200 million commitment with a $15 million letter of credit sublimit.
- Term Loans: $250 million payable in quarterly installments, maturing in full on July 29, 2025.
- Interest Rates: Base rate or Adjusted LIBOR plus an Applicable Margin ranging from 1.50% to 3.75% based on leverage.
- Covenants: Consolidated Total Leverage Ratio capped at 3.75 to 1.00, stepping down to 3.25 to 1.00.
- Debt Repayment: Proceeds from the Notes and new Term Loans were used to repay all outstanding obligations under the Prior Credit Agreement.
Material Changes Versus Prior Period
The Company terminated its Third Amended and Restated Credit and Guaranty Agreement (the "Prior Credit Agreement") and replaced it with a new Credit Agreement. This restructuring involved:
- Issuing $350 million in unsecured senior notes.
- Establishing a new secured credit facility totaling $450 million ($200 million revolver + $250 million term loan).
- Shifting the maturity profile of debt, with the new notes extending to 2028 and the new credit facility maturing in 2025.
Outlook, Risks, and Unusual Items
Management Commentary and Use of Proceeds: Net proceeds from the Notes were used to repay a portion of the Prior Credit Agreement term loans and pay related fees. Remaining proceeds are designated for general corporate purposes. The new Credit Agreement allows for working capital, capital expenditures, and permitted acquisitions.
Redemption Provisions: The Notes are redeemable at the Company's option after August 1, 2023, at specified premiums declining to 100% by 2026. Early redemption before 2023 is possible at a "make-whole" premium or up to 40% with equity offering proceeds at 106.125%.
Risks and Contingencies:
- Subordination: The Notes are effectively subordinated to secured debt (including the new Credit Agreement) and structurally subordinated to liabilities of non-guarantor subsidiaries.
- Covenants: The Credit Agreement includes restrictions on additional indebtedness, liens, and asset transactions, as well as mandatory prepayment requirements based on asset dispositions and excess cash flow.
- Events of Default: Includes standard defaults plus specific compliance with healthcare laws.
Financial Metrics: The filing text does not provide specific values for revenue, profit, cash flow, or margins for the reporting period.
Investor Verification Checklist
- Verify the exact amount of net proceeds retained for "general corporate purposes" after debt repayment and fee payments.
- Review the full text of the Indenture (Exhibit 4.1) and Credit Agreement (Exhibit 10.1) for detailed covenant calculations and definitions of "Consolidated Total Leverage Ratio."
- Confirm the Company's current leverage ratio to assess compliance with the 3.75 to 1.00 covenant cap.
- Monitor the Company's ability to meet quarterly term loan payments starting September 2020.
- Assess the impact of the 6.125% interest rate on future interest expense compared to the prior credit facility rates.